BBIO Stock Forecast & Price Target

BridgeBio Pharma is a biotech company with a strong late-stage pipeline, including Attruby for transthyretin amyloid cardiomyopathy. Their diversified pipeline and potential for multiple approved treatments provide a solid foundation for future growth. The recent positive data from their PROPEL 3 study for their drug infigratinib supports their competitive position in the ATTR-CM market and may drive a "stabilizer-first" approach for newly diagnosed patients in the market. However, risks to the company include clinical trial failures, delays in approval filings, pricing pressure, and potential dilution from financing efforts.

BridgeBio Pharma is facing significant challenges as it continues to invest in clinical trials and build out its sales and medical teams, leading to high expenses and a negative cash flow. The company's plans for launching its key drug, Attruby, in the US and EU are not expected to generate significant revenue until mid-2027 at the earliest, and there is uncertainty around the drug's success in a market with existing competitors. The upcoming PDUFA date for encaleret in ADH1 also poses a risk, with only 2.2K unique patients identified and ongoing challenges in enrollment for clinical studies.